Two market‑moving developments accelerated the oral GLP‑1 race this week: Novo Nordisk reported more than 3,000 prescriptions for its newly launched Wegovy oral pill in the first week, signaling rapid early uptake, while Eli Lilly said the FDA is expected to decide on its oral candidate, orforglipron, in the second quarter after granting a national priority review pathway. Novo’s launch metrics show immediate patient and prescriber demand for an oral GLP‑1 option; Lilly says a swift review could position orforglipron to compete closely with Wegovy’s pill. Company statements tied the dynamics to increasing use of cash‑pay and online pharmacy channels. GLP‑1 pills are oral formulations designed to mimic the appetite‑suppressing effects of injectable GLP‑1 receptor agonists; their arrival expands patient access beyond injectables and shifts commercial strategies across the obesity drug market.